
摩根大通表示,尽管该行业的海外势头依然强劲,但基础研究滞后以及迫在眉睫的地缘政治风险,将对中国构建世界级生物技术创新生态系统的努力构成压力。
A lag in foundational research and looming geopolitical risks will weigh on China’s bid to build a world-class biotechnology innovation ecosystem, even as the sector’s overseas momentum remains strong, according to JPMorgan.
摩根大通中国医疗健康研究主管黄杨(Yang Huang)周三在接受采访时表示:“在中国,基础研究方面仍有一些需要迎头赶上的地方,特别是在生物学和药物研究方面。”
“In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare research at JPMorgan, during an interview on Wednesday.
黄杨在香港出席这家投资银行的亚太科技、创新与增长会议期间在场边表示,为实现中国生物医药产业新五年规划中制定的“雄心勃勃的目标”,中国需要专注于推动科学前沿的基础研究。
To meet the “ambitious goal” set in the country’s new five-year plan for the biopharmaceutical industry, China will need to focus on basic research that pushes the scientific frontier, according to Huang, who was speaking on the sidelines of the investment bank’s APAC Technology, Innovation and Growth conference in Hong Kong.
北京在9月发布的规划中表示,到2030年,中国应“稳居全球生物医药创新前列”,中国本土原研首创(first-in-class)创新药占全球总数的比例至少达到四分之一。
Beijing said the country should “firmly rank at the global forefront” for biopharmaceutical innovation by 2030 in the plan released in September, with China-originated first-in-class innovative drugs accounting for at least one-quarter of the global total.
黄杨表示,生产这些药物需要中国高校和实验室进行“大量投资”和“持续工作”以推进基础研究。
Producing these drugs would require “significant investment” and “continued work” from Chinese universities and labs to advance basic research, Huang said.
近年来,中国作为生物技术创新枢纽的角色迅速增长,全球制药巨头越来越从中国采购药物资产。中国国家发展改革委上个月表示,今年以来,涉及中国自主研发创新药的对外授权(out-licensing)交易额已达到1300亿美元,接近2025年全年的总额。
China’s role as a biotech innovation hub has grown rapidly in recent years, with global pharmaceutical giants increasingly sourcing drug assets from the country. The value of out-licensing deals involving China-developed innovative drugs had reached US$130 billion so far this year, approaching the full-year total for 2025, China’s National Development and Reform Commission said last month.
不过黄杨指出,授权给海外合作伙伴的中国创新药,目前大多并非首创药物。
Most of the Chinese innovative drugs licensed to overseas partners, however, are currently not first-in-class, Huang noted.
黄杨表示,中国建设世界领先生物技术产业的努力也可能面临地缘政治障碍,因为这项工作需要中国能够直接接触发达市场。
China’s push to build a world-leading biotech industry could also face geopolitical barriers, as the effort requires the country to have direct access to developed markets, according to Huang.
他表示,目前的外部授权主流商业模式下,中国生物技术公司依赖海外合作伙伴来开发和商业化其药物,但少数行业领头羊“可以考虑自己做事”。
Chinese biotech firms currently rely on overseas partners to develop and commercialise their drugs under the dominant out-licensing business model, but a few industry leaders “could consider doing things by themselves”, he said.
黄杨补充说,建立这种独立性仍然是一个长期目标,将延续到未来三到五年之后,并可能取决于全球地缘政治格局等因素。
Building this independence, however, remained a long-term goal stretching beyond the next three to five years and could be contingent on factors including the global geopolitical landscape, Huang added.
随着中国在该行业崛起,华盛顿加大了对跨境生物医药合作的审查力度。
Washington has ramped up its scrutiny of cross-border biopharmaceutical collaboration amid China’s rise in the industry.
美国财政部上个月根据《全面对外投资国家安全法》(Comprehensive Outbound Investment National Security Act, 简称Coins)提出了新规则,如果获得批准,将限制美国对包括中国在内的特定国家的生物技术投资。
The US Treasury Department last month proposed new rules under the Comprehensive Outbound Investment National Security (Coins) Act, which, if approved, would curb US biotech investments in certain nations including China.
与此同时,《生物安全法》(Biosecure Act)将禁止接受联邦资金和合同的实体与“受关注的生物技术公司”进行业务往来,预计今年年底前将公布黑名单公司名单。
The Biosecure Act, meanwhile, will prohibit entities that receive federal funding and contracts from doing business with “biotechnology companies of concern”, with a list of blacklisted companies expected to be released by the end of this year.
黄杨表示,此类地缘政治风险仍然是许多关注中国医疗健康行业的投资者的焦点,他将该行对该行业2027年的展望描述为“谨慎乐观”。
Such geopolitical risks remained a focal point for many investors watching China’s healthcare sector, Huang said, describing the investment bank’s 2027 outlook for the sector as “cautiously optimistic”.
黄杨说:“中国医疗健康公司的最佳做法是保持耐心,同时继续加强研发能力。”
“The best approach for Chinese healthcare companies is to remain patient while continuing to strengthen their research and development capabilities,” Huang said.
他补充说,尽管如此,中国该行业仍提供了高增长潜力,对于希望将风险敞口从人工智能和硬件转移出去的投资者而言,可以起到防御性投资的作用。”
Still, the Chinese sector offered high growth potential and could serve as a defensive play for investors looking to rotate their exposure away from artificial intelligence and hardware, he added.